Corrigendum to “Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest” (Translational Oncology (2022) 15(1), (S1936523321002503), (10.1016/j.tranon.2021.101259))

The authors regret inadvertent errors in the methods for the in vivo monoclonal antibody treatment, specifically the monoclonal antibody dose and the isotype control clone. In the Materials and methods section on in vivo treatment, the sentence on anti-PD-1 treatment should read: For evaluation of the efficacy of PCC in combination with anti-PD-1 mAb, mice were treated with 1) vehicle control IT daily for 15 doses and 10 mg/kg rat IgG2a, κ isotype control mAb (BioXCell, Lebanon, NH, Cat. No. BE0089, clone 2A3) intraperitoneal (IP) every three days for the duration of the experiment; 2) PCC 20 mg/kg IT daily for 15 doses; 3) 10 mg/kg anti-PD-1 mAb (BioXCell, Cat. No. BE0146, clone RMP1–14) IP every three days for the duration of the experiment; or 4) PCC 20 mg/kg IT daily for 15 doses and 10 mg/kg anti-PD-1 IP every three days for the duration of the experiment. The sentence in the legend for Figure 4E should read: Mice treated with anti-PD-1 received 10 mg/kg IP every three days, starting on day 1 for the duration of the experiment. The authors would like to apologise for any inconvenience caused. DOI of original article: https://doi.org/10.1016/j.tranon.2021.101259